Home > Healthcare > Pharmaceuticals > Vaccines > Cancer Vaccine Market
Cancer Vaccine Market Size
- Report ID: GMI10285
- Published Date: Jul 2024
- Report Format: PDF
Cancer Vaccine Market Size
Cancer Vaccine Market size was valued at around USD 9.1 billion in 2023 and is estimated to grow at 11.2% CAGR from 2024 to 2032. Cancer vaccines are immunotherapies designed to stimulate the immune system to recognize and attack cancer cells, either by preventing cancer (prophylactic) or treating existing cancers (therapeutic). Preventive vaccines, such as those for HPV and Hepatitis B, aim to prevent cancers caused by these viruses, while therapeutic vaccines, such as sipuleucel-T for prostate cancer, target cancer-specific antigens to elicit an immune response.
The rising prevalence of cancer is a significant driving factors for the market. For instance, according to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide. This underscores the critical need for innovative treatments and preventive measures, highlighting the pivotal role of cancer vaccines in potentially reducing cancer incidence and mortality.
Furthermore, advancements in biotechnology and immunotherapy, growing demand for personalized medicine, and rising geriatric population, are the promoting factors advancing the growth of the market.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Cancer Vaccine Market Size in 2023: | USD 9.1 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 11.2% |
| 2024 – 2032 Value Projection: | USD 23.4 Billion |
| Historical Data for: | 2021 – 2023 |
| No. of Pages: | 195 |
| Tables, Charts & Figures: | 288 |
| Segments covered: | Type, Technology, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Cancer Vaccine Market Scope
